Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimizing Dosing of Colistin for Infections Resistant to all Other Antibiotics
2010-021413-23Phase 4Completed
- Sponsor
- National and Kapodistrian University of Athens School of Medicine
- Start
- Aug 2010
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of colistin in multidrug-resistant Gram-negative bloodstream infection (MDR-GNBSI), hospital-acquired pneumonia (HAP) and Bacteremia, sponsored by National and Kapodistrian University of Athens School of Medicine. Primary endpoints: Plasma disposition of colistin and Colistin clearance via renal replacement therapy. Started Aug 2010; status: completed.
02
Drugs
colistin
03
Conditions
multidrug-resistant Gram-negative bloodstream infection (MDR-GNBSI)hospital-acquired pneumonia (HAP)Bacteremia
Beyond the preview
Go deeper on 2010-021413-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021413-23.